Provided by Tiger Trade Technology Pte. Ltd.

Biogen

201.18
+15.828.53%
Post-market: 200.00-1.1800-0.59%19:50 EST
Volume:3.40M
Turnover:670.34M
Market Cap:29.51B
PE:18.33
High:202.41
Open:187.01
Low:184.60
Close:185.36
52wk High:202.41
52wk Low:110.04
Shares:146.70M
Float Shares:146.23M
Volume Ratio:1.89
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):10.97
EPS(LYR):11.21
ROE:7.39%
ROA:6.14%
PB:1.62
PE(LYR):17.95

Loading ...

Biogen price target raised to $200 from $190 at Wells Fargo

TIPRANKS
·
1 hour ago

Biogen price target raised to $190 from $156 at Morgan Stanley

TIPRANKS
·
1 hour ago

Biogen price target raised to $215 from $185 at Citi

TIPRANKS
·
1 hour ago

Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold

TIPRANKS
·
5 hours ago

Analysts Offer Insights on Healthcare Companies: Centene (CNC) and Biogen (BIIB)

TIPRANKS
·
5 hours ago

Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating

TIPRANKS
·
5 hours ago

Biogen Trial Updates Test Investor Views On Pipeline Strength And Valuation

Simply Wall St.
·
Feb 07

Biogen Earnings Call: Solid 2025, Cautious 2026 Outlook

TIPRANKS
·
Feb 07

Biogen Inc. Stock Rallies 8.5%, Outperforms Peers

Dow Jones
·
Feb 07

Biogen price target raised to $196 from $165 at BMO Capital

TIPRANKS
·
Feb 07

BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina

Reuters
·
Feb 07

Stifel Nicolaus Adjusts Biogen PT to $214 From $202, Maintains Buy Rating

MT Newswires Live
·
Feb 07

BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison

Reuters
·
Feb 06

Stock Track | Biogen Soars 5.13% Intraday on Strong Q4 Earnings Beat and Above-Expectations 2026 Profit Outlook

Stock Track
·
Feb 06

Biogen Shares up 1.2% After Co Forecast 2026 Profit Above Estimates

THOMSON REUTERS
·
Feb 06

Wedbush Keeps Their Hold Rating on Biogen (BIIB)

TIPRANKS
·
Feb 06

Biogen Exec Says Potential for Acceleration in Leqembi Growth Going Into 2027

THOMSON REUTERS
·
Feb 06

Biogen Exec Says Looking at Late-Stage M&a Targets No More Than Around $5 Bln to $6 Bln

THOMSON REUTERS
·
Feb 06

Biogen Exec Says Co Expects 2026 Sales for MS Products, Excluding Vumerity, to Decline by Mid Teen Percentage Versus 2025

THOMSON REUTERS
·
Feb 06

Biogen CEO Says Leqembi Iqlik Eligible for Part D Reimbursement, Won't Be Fully Reimbursed Until January 1, 2027 - Conf Call

THOMSON REUTERS
·
Feb 06